Viatris launches RYZUMVl 0.75% in US

The average time of dilation lasts three to eight hours

Akums gets approval for triple combination diabetes treatment

Boehringer Ingelheim and Click Therapeutics expand collaboration to develop digital therapeutics for schizophrenia

Healthium launches Theruptor Novo for diabetic foot ulcers

Theruptor Novo is a best in class patented product which provides an optimum healing environment and addresses the concerns of chronic wound dressing

Enveda appoints Vanitha Sekar as Chief Business Officer

She joins Enveda from Gilead Sciences

Weizmann’s study sheds new light on a promising antidepressant

A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression

Evonik to build new lipid production facility for mRNA-based therapies in U.S.

Construction will begin in early 2023, and the plant is scheduled to go onstream in 2025

Camzyos is the first and only USFDA-approved cardiac myosin inhibitor

Approval based on groundbreaking Phase 3 EXPLORER-HCM trial demonstrating benefit in patients receiving Camzyos versus placebo

Lo.Li Pharma International seeks partners for Deplesin therapy

Deplesin is an add-on therapy to gold standard agents like lithium, valproic acid, and carbamazepine, supporting patients in ways that prescription medications often cannot

NH TherAguix releases new batch for AGuIX

The release of this batch will secure the supply for hospitals and cancer centres that are involved in the clinical trials managed by the company